-
Salesforce Q1 Results 'Uninspiring': 'Nothing To Dispel The AI Threat Narrative'
Thursday, May 28, 2026 - 12:37pm | 914Read More...Salesforce Inc (NYSE:CRM) analysts mostly maintain their ratings and price targets, with some figures lowered, after the company reported first-quarter financial results on Wednesday. • Salesforce stock is gaining positive traction. Why is CRM stock advancing? The Salesforce Analysts DA...
-
PayPay To Generate 'Outsized Earnings Growth' For 5-10 Years: Analysts
Monday, April 6, 2026 - 11:06am | 362Read More...Tokyo-based electronic payment company PayPay Corp (NASDAQ:PAYP) made its US stock market debut on March 12. Here are the key analyst insights: Benchmark analyst Mark Palmer initiated coverage with a Buy rating and price target of $31. Cantor Fitzgerald analyst Ryan Campbell began coverage with an...
-
Nvidia Analysts See Stock 'Best Positioned In AI,' Not Worried About Guidance: 'All Systems Go For Blackwell Ramp'
Thursday, November 21, 2024 - 1:31pm | 1099Read More...NVIDIA Corporation (NASDAQ:NVDA) analysts highlight the company's strong beat in the third quarter and guidance in the fourth quarter that may leave investors less confident in the short term. The NVDA Analysts: Cantor Fitzgerald analyst C.J. Muse reiterated an Overweight rating on Nvidia with a $...
-
Cantor Fitzgerald Lowers GW Pharmaceuticals Price Target
Monday, December 3, 2018 - 4:01pm | 443Read More...Less than a week after its most recent update on GW Pharmaceuticals plc (NASDAQ: GWPH), Cantor Fitzgerald lowered its price target for the stock Monday after the issuance of the company's 10-K report. The Analyst Analyst Elemer Piros reiterated an Overweight on GW...
-
What Do Zogenix Drug Study Results Mean For GW Pharmaceuticals' Epidiolex?
Monday, October 2, 2017 - 1:36pm | 389Read More...Zogenix, Inc. (NASDAQ: ZGNX) shares jumped another 5.6 percent Monday morning after exploding higher by 172 percent Sept. 29 in the wake of positive data on anti-epileptic drug ZX008. Shares of GW Pharmaceuticals PLC-ADR (NASDAQ: GWPH) plummeted 9.6 percent last Friday as well, and dropped another...
-
Clearing Up Misconceptions Surrounding Aerie Pharmaceuticals
Thursday, October 6, 2016 - 3:46pm | 210Read More...Cantor Fitzgerald reiterated its Buy rating and $50 price target on Aerie Pharmaceuticals Inc (NASDAQ: AERI), as the company provided new clinical data to clear up residual misconceptions and uncertainties regarding the Roclatan Phase 3 trial. Analyst Elemer Piros noted that Aerie enrolled...
-
Internet Stocks Outperformed The Market During Brexit Week
Friday, July 1, 2016 - 12:23pm | 316Read More...Investors appear to have fled to Internet stocks for safety following the Brexit vote, which introduced a lot of volatility and uncertainty in the market. According to Youssef Squali of Cantor Fitzgerald, Internet stocks proved to be "resilient" after a week of "price gyrations." The sector ended...
-
Cantor Fitzgerald Initiates The Rubicon Project With Buy Rating, $22 Target
Tuesday, April 5, 2016 - 8:48am | 250Read More...Cantor Fitzgerald’s Youssef Squali expects The Rubicon Project Inc (NYSE: RUBI) to benefit going forward from the “secular tailwinds” in digital advertising. The analyst initiated coverage of the company with a Buy rating and price target of $22. Advertising Tailwinds...
-
Is Yahoo In A Win-Win-Win Situation?
Thursday, December 3, 2015 - 11:54am | 475Read More...Shares of Yahoo! Inc. (NASDAQ: YHOO) gained more than 5 percent on Wednesday after news reports surfaced the company is exploring a potential sale of its core Internet business. Youssef Squali of Cantor Fitzgerald maintained a Buy rating with a $44 price target but a probability-weighted...
-
Cantor Still Expects Threshold Pharma To More Than Triple, Says 2016 Will Be 'Data Rich' Year
Thursday, July 2, 2015 - 9:09am | 302Read More...In a report published Thursday, Cantor Fitzgerald analyst Daniel Brims maintained a Buy rating and $14 price target on Threshold Pharmaceuticals, Inc. (NASDAQ: THLD). The analyst believes that Evofosfamide and TH-4000 could be key catalysts for the stock on 2016. Existing EGFR inhibitors are found...
-
Cantor Reiterates Buy On LinkedIn, Issues 'Clearing Up'
Sunday, June 28, 2015 - 1:18pm | 284Read More...In a report published Friday, Cantor Fitzgerald analyst Youssef Squali reiterated a Buy rating and $254 price target on LinkedIn Corp. (NYSE: LNKD). With the stock trading more than 20 percent below its high, LinkedIn offers an attractive risk/reward profile. The company's new social selling...
-
Cantor Downgrades Lumber Liquidators, Slashes Targets On 'Too Many' Risks
Tuesday, May 19, 2015 - 8:31am | 282Read More...In a report published Tuesday, Cantor Fitzgerald analysts downgraded the rating on Lumber Liquidators Holdings Inc (NYSE: LL) from Buy to Hold. The price target was lowered from $42 to $26. The analysts believe that the company is facing several regulatory and legal risks at present. "We don't...
-
What Could Be Coming For Cisco, According To Cantor Fitzgerald
Tuesday, May 12, 2015 - 10:35am | 179Read More...In a report published Tuesday, analysts at Cantor Fitzgerald maintained their Buy rating on Cisco Systems, Inc. (NASDAQ: CSCO). The price target was set to $33. The analysts expect the company to report strong 3Q:FY15 results. The analysts expect Cisco to report strong results for Q3, driven by...
-
Wall Street Voices Opinion On Apple Watch
Monday, April 27, 2015 - 1:34pm | 669Read More...Apple Inc. (NASDAQ: AAPL) will report earnings after Monday's market close. Ahead of the results several Wall Street firms gave their opinion on Apple's newest product, the Apple Watch. Goldman Sachs Bill Shope and Matthew Cabral wrote: "Apple sold out of all Watch inventory to...
-
Does AOL's New Ad Platform Make It A Buy?
Wednesday, April 15, 2015 - 11:21am | 162Read More...In a report published Wednesday, Cantor Fitzgerald analysts maintained their Buy rating on AOL, Inc (NYSE: AOL) as well as their price target of $45. AOL launched ONE in North America Wednesday morning. ONE is AOL's "open, unified programmatic platform, which enables marketers to optimize campaign...











